Ottimo Pharma is advancing bifunctional medicines with a lead asset, Jankistomig, a first‑in‑class PD1/VEGFR2 bifunctional antibody being developed in both IV and SC forms. The company is conducting IND‑enabling studies for Jankistomig and plans to file an IND in late 2025. Ottimo emerged from stealth in October 2024 and was co‑founded by Medicxi and Jonny Finlay in 2020. The program is positioned to target immune checkpoint inhibition and angiogenesis simultaneously, aiming to offer a wider therapeutic window regardless of tumor VEGF levels. Management has been strengthened with senior hires in finance, technical/quality, and legal functions to support clinical and CMC advancement. The company highlights a potential addressable global oncology market valued at well over $50 billion and has secured substantial Series A funding to progress its pipeline.

Total raised

$140M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2024